Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5520108 | 0.81 | POLB (0.39) | RAB9ANPC1POLBMAPTALDH1A1 | |
| SCHEMBL5525613 | 0.78 | P2RX7 (0.40) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5521998 | 0.77 | HCAR2 (0.46) | RAB9ANPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5527532 | 0.77 | SMN1; SMN2 (0.48) | RAB9ANPC1POLBMAPTALDH1A1 | |
| SCHEMBL5524260 | 0.76 | PPARA (0.40) | RAB9AMAPTTP53SMN1; SMN2KDM4E | |
| SCHEMBL5522358 | 0.76 | RAB9A (0.51) | RAB9ANPC1POLBMAPTALDH1A1 | |
| SCHEMBL5527609 | 0.76 | CACNA1G (0.38) | RAB9ANPC1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL5528337 | 0.75 | NPC1 (0.45) | RAB9ANPC1POLBALDH1A1HTT | |
| SCHEMBL5522334 | 0.74 | SMN1; SMN2 (0.39) | RAB9ANPC1POLBALDH1A1MEN1 | |
| SCHEMBL5520170 | 0.74 | KMT2A (0.46) | RAB9ANPC1POLBKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108565-A1 | PYRROLE CARBOXYLIC ACID DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
| US-20120108565-A1 | PYRROLE CARBOXYLIC ACID DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108565-A1 | PYRROLE CARBOXYLIC ACID DERIVATIVES AS ANTIBACTERIAL AGENTS | POLI, POLB, POLA1 | RAB9A 3225/4885NPC1 3623/4885POLB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.